INTRODUCTION
Hepatoblastoma is the most common malignant liver tumor and the third most common intra-abdominal neoplasm in children. The survival of patients with a hepatoblastoma has markedly improved in recent years with the advances in chemotherapy and surgery. Several national and international cooperative studies have shown that the prognosis for hepatoblastoma can be improved dramatically by combining surgery with pre-and post-operative chemotherapeutic agents such as cisplatin and adriamycin [1, 2] . Complete resection is the primary goal of surgical treatment and a prerequisite for cure, and effective neoadjuvant chemotherapy is important for complete re-These courses were repeated every 4 weeks and the patients were re-assessed for the tumor resectability after 4 courses. If the tumor was deemed resectable, patients were referred to one of our authors (LSK) for complete resection. If deemed unresectable, patients were treated with another 2 courses followed by re-evaluation for resection.
The liver transplantation was planned for patients deemed unresectable at this point. Regardless of the resectability, a maximum of 6 courses were given preoperatively. Standard anatomical resection was attempted, and clear resection margins were confirmed during the operation. Metastatic lesions that persisted after the preoperative chemotherapy were removed surgically, if possible. Complete resection was defined as no residual tumor by macroscopic or microscopic findings. All patients underwent postoperative chemotherapy with the same regimen, which was repeated up to a total of six courses until the serum α-fetoprotein (AFP) returned to the normal range.
Evaluation of treatment response
Assessment of response to the treatment was performed with AFP and CT after completion of the required treatment. The definitions used were as follow: complete response (CR) was no evidence of disease after complete resection and normal AFP; partial response (PR) was any tumor size decrease associated with decreased AFP (＞1 log less than the original value); stable disease (SD) was no tumor size change and no change or less than 1 log decrease of AFP; and progressive disease (PD) was unequivocal increase in size of the tumor and/or any unequivocal increase of AFP.
Outcome measure
The main outcome measure was overall and event-free survival. Secondary outcome measures included CR, PR, SD, and PD. An event was defined as the disease-related patient death or disease relapse. Survival time was defined as the time from the diagnosis to the event.
RESULTS
Clinical features of the 27 patients with hepatoblastoma (Table 1) The median age at the time of the diagnosis was 18 months (range, 2 months to 12.6 years), and the gender dis- One patient underwent living-related liver transplantation for the recurrent tumor after post-operative chemotherapy. 
Surgical and pathological results
Six patients underwent complete surgical excision as primary therapy without preoperative chemotherapy: five patients in group I for readily resectable tumors (3 sectionectomies, 2 right hemihepatectomies) and one patient in group II for a ruptured tumor (emergency surgery, right hemihepatectomy). One patient (group IV) underwent primary liver transplantation for bilateral multiple hepatoblastomas, which was initially misdiagnosed as hepatocellular carcinoma after percutaneous biopsy. For the remaining 20 patients (7 group II patients and 13 group III patients), preoperative chemotherapy was administered and complete tumor excision was achieved thereafter.
There were 6 hemihepatectomies and 1 sectionectomy in group II patients, and 4 trisectioinectomies, 7 hemihepatectomies, 2 sectionectomies in group III patients. In group III, seven unresectable cases were rendered resectable after preoperative chemotherapy (Fig. 1) . Postoperative chemotherapy was administered in all patients regardless of the PRETEXT classification except in the one patient who underwent primary liver transplantation. The pathological results and the treatment courses are summarized in Table 1 and Table 2 , respectively.
Treatment outcome according to the PRETEXT classification (Table 2)
The median follow-up duration was 6. One patient underwent living-related liver transplantation for the recurrent tumor after partial hepatectomy. The cause of death was CMV hepatitis and bone marrow suppression during the postoperative CTx, respectively.
e)
The cause of death was metachronous rectal cancer and primary nonfunction after liver transplantation, respectively. 87.8%, while 5-year EFS by PRETEXT grouping was 100%, 75%, 92% and 100% for group I to IV, respectively (Fig. 2) .
DISCUSSION
The goal of this study was to review our experience with to those from Europe and United States [8] . However, the Japanese trial used staging criteria somewhat different from those of the PRETEXT classification, and therefore a direct comparison with our results cannot be made. Suita et al. [9] recently published the findings of improved survival with the JPLT-1 protocol with results similar to this study. They concluded that the combination of cisplatin-adriamycin could improve survival by increasing the resectability of the tumor or by improving the cure rate in cases with incomplete tumor resection. In this study, most of the patients in group III benefitted from neoadjuvant chemotherapy with a similar regimen and could achieve complete tumor resection, thus showing the usefulness of the regimen as a preoperative treatment. However, as there were no cases with an incomplete resection in this study, the benefit of this regimen on residual tumor could not be evaluated.
The survival of patients with hepatoblastoma is usually correlated with the PRETEXT classification; group I being the best and group IV the worst [9, 10] . By contrast, our results showed the worst survival in group II and the best survival in groups I and IV. We speculate that this is probably due to low patient number. Moreover, the causes of death in the group II patients might have been prevented by different medical management; although the post-chemotherapy myelodysplastic syndrome was difficult to predict and fatal if affected, CMV hepatitis could have been treated preoperatively by careful patient evaluation and the patient death would have been prevented. Therefore, the survival of group II patients might have been similar or even better than group III with different medical intervention. Most recently published paper showed the improved survival in PRETEXT IV patients with dose-intensive chemotherapy and surgery [7] , and similar results were obtained with total hepatectomy and liver transplantation [11] . In our study, only one case in group IV was successfully treated with a liver transplantation and the chemotherapeutic regimen was different. Therefore, the comparison of the survival would seem inappropriate, but we expect long-term disease-free survival in this patient.
Transplantation after tumor recurrence, the so called "rescue transplantation", has a much worse survival rate compared to primary transplantation [11, 12] . Some investigators have suggested that recurrence of a tumor after a primary resection is a relative contraindication to transplantation [13] . Although this series had only two cases of transplantation (one primary and one rescue) for hepatoblastoma, our experience is consistent with previously re- 
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